Optimization of process variables of zanamivir-loaded solid lipid nanoparticles and the prediction of their cellular transport in Caco-2 cell model

International Journal of Pharmaceutics

Volumn 478, Issue 1, 2015, Pages 60-69

  Shi, Li Li ^a   Cao, Yue ^a   Zhu, Xiao Yin ^a   Cui, Jing Hao ^a   Cao, Qing Ri ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

Caco 2 cell; Cellular transport; Process variables; Solid lipid nanoparticles; Zanamivir

Indexed keywords

GLYCEROL BEHENATE; GLYCEROL PALMITOSTEARATE; GLYCEROL STEARATE; POLOXAMER; POLYVINYL ALCOHOL; SOLID LIPID NANOPARTICLE; ZANAMIVIR; ACYLGLYCEROL; ANTIVIRUS AGENT; DIACYLGLYCEROL; FATTY ACID; NANOPARTICLE; SURFACTANT;

APICAL MEMBRANE; ARTICLE; CACO 2 CELL LINE; CELL GROWTH; CELL TRANSPORT; CELL VIABILITY; CONTROLLED STUDY; CRYSTALLIZATION; DISPERSION; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG SOLUTION; ENDOCYTOSIS; ENDOSOME; EXOCYTOSIS; GASTROINTESTINAL ABSORPTION; IN VITRO STUDY; INFRARED SPECTROSCOPY; INTERNALIZATION; INTESTINE EPITHELIUM; LYSOSOME; MTT ASSAY; NANOEMULSION; NANOENCAPSULATION; PARTICLE SIZE; PH; PHYSICAL CHEMISTRY; PREDICTION; PROCESS OPTIMIZATION; SURFACE CHARGE; SUSTAINED DRUG RELEASE; TRANSCYTOSIS; TRANSMISSION ELECTRON MICROSCOPY; ULTRASOUND; X RAY DIFFRACTION; ZETA POTENTIAL; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG RELEASE; HUMAN; SOLUBILITY; TRANSPORT AT THE CELLULAR LEVEL; ULTRASTRUCTURE;

ANTIVIRAL AGENTS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CELL SURVIVAL; DIGLYCERIDES; DRUG LIBERATION; FATTY ACIDS; GLYCERIDES; HUMANS; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; POLOXAMER; POLYVINYL ALCOHOL; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SURFACE-ACTIVE AGENTS; X-RAY DIFFRACTION; ZANAMIVIR;

EID: 84910611388     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.11.017     Document Type: Article

References (50)

1. B. Ana, A.S. Maria, R.G. Alicia, P.R. Ana del, R. Anne des, and P. Veronique Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier J. Control. Release 166 2013 115 123
2. F. Antunes, F. Andrade, F. Araujo, D. Ferreira, and B. Sarmento Establishment of a triple co-culture in vitro cell models to study intestinal absorption of peptide drugs Eur. J. Pharm. Biopharm. 83 2013 427 435
3. A. Beloqui, M. Ángeles Solinís, A.R. Gascón, A. del Pozo-Rodríguez, A. des Rieux, and V. Préat Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier J. Control. Release 166 2013 115 123
4. V. BeÍrard, E. Lesniewska, C. Andrès, D. Pertuy, C. Laroche, and Y. Pourcelot Dry powder inhaler: influence of humidity on topology and adhesion studied by AFM Int. J. Pharm. 232 2002 213 224
5. L.M. Bimbo, E. Mäkilä, T. Laaksonen, V.P. Lehto, J. Salonen, J. Hirvonen, and H.A. Santos Drug permeation across intestinal epithelial cells using porous silicon nanoparticles Biomaterials 32 2011 2625 2633
6. B. Boonyapiwat, N. Sarisuta, and S. Kunastitchai Characterization and in vitro evaluation of intestinal absorption of liposomes encapsulating zanamivir Curr. Drug Deliv. 8 2011 377 392
7. M. Boyd, V. Risovic, P. Jull, E. Choo, and K.M. Wasan A stepwise surgical procedure to investigate the lymphatic transport of lipid-based oral drug formulations: cannulation of the mesenteric and thoracic lymph ducts within the rat J. Pharmacol. Toxicol. Methods 49 2004 115 120
8. Q.R. Cao, H.N. Wu, L. Zhu, D. Wu, Y.F. Zhu, Z.X. Zhu, and J.H. Cui Preparation and evaluation of zanamivir-loaded solid lipid nanoparticles J. Control. Release 152 2011 e2 e4
9. L.M. Cass, C. Efthymiopoulos, and A. Bye Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers Clin. Pharmacokinet. 36 1999 1 11
10. H.J. Cho, J.W. Park, I.S. Yoon, and D.D. Kim Surface-modified solid lipid nanoparticles for oral delivery of docetaxel: enhanced intestinal absorption and lymphatic uptake Int. J. Nanomed. 9 2014 495 504
11. P.C. Christophersen, L. Zhang, A. Müllertz, H.M. Nielsen, M.S. Yang, and H.L. Mu Solid lipid particles for oral delivery of peptide and protein drugs II - the digestion of trilaurin protects desmopressin from proteolytic degradation Pharm. Res. 31 2014 2420 2428
12. R.A. Cone Barrier properties of mucus Adv. Drug Deliv. Rev. 61 2009 75 85
13. F. Danhier, E. Ansorena, J.M. Silva, R. Coco, A. Le Breton, and V. Préat PLGA-based nanoparticles: an overview of biomedical applications J. Control. Release 161 2012 505 522
14. A.A. Date, M.D. Joshi, and V.B. Patravale Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles Adv. Drug Deliv. Rev. 59 2007 505 521
15. D.R. de Araújo, D.C. da Silva, R.M. Barbosa, M. Franz-Montan, C.M. Cereda, C. Padula, P. Santi, and E. de Paula Strategies for delivering local anesthetics to the skin: focus on liposomes solid lipid nanoparticles, hydrogels and patches Exp. Opin. Drug Deliv. 10 2013 1551 1563
16. S. Doktorovova, E.B. Souto, and A.M. Silva Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers - a systematic review of in vitro data Eur. J. Pharm. Biopharm. 87 2014 1 18
17. Y. Dong, W.K. Ng, S. Shen, S. Kim, and R.B. Tan Solid lipid nanoparticles: continuous and potential large-scale nanoprecipitation production in static mixers Colloids Surf. B: Biointerfaces 94 2012 68 72
18. N. Erk A validated HPLC method for the determination of the neuraminidase inhibitor, zanamivir (GG167), in spiked human plasma and in pharmaceutical formulations J. Liquid Chromatogr. R. T. 27 2005 1541 1552
19. J.F. Fangueiro, T. Andreani, M.A. Egea, M.L. Garcia, S.B. Souto, A.M. Silva, and E.B. Souto Design of cationic lipid nanoparticles for ocular delivery: development, characterization and cytotoxicity Int. J. Pharm. 461 2014 64 73
20. J.H. Finke, H. Schmolke, C.P. Klages, and C.C. Müller-Goymanna Controlling solid lipid nanoparticle adhesion by polyelectrolyte multilayer surface modifications Int. J. Pharm. 449 2013 59 71
21. C. Freitas, and R.H. Muller Correlation between long-term stability of solid lipid nanoparticles (SLNs) and crystallinity of the lipid phase Eur. J. Pharm. Biopharm. 47 1999 125 132
22. N. Ghalandarlaki, A.M. Alizadeh, and S. Ashkani-Esfahani Nanotechnology- applied curcumin for different diseases therapy Biomed. Res. Int. 2014 2014 1 23
23. E.H. Gokce, G. Sandri, M.C. Bonferoni, S. Rossi, F. Ferrari, T. Güneri, and C. Caramella Cyclosporine A loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity Int. J. Pharm. 364 2008 76 86
24. S.V. Gupta, D. Gupta, J. Sun, A. Dahan, Y. Tsume, J. Hilfinger, K.D. Lee, and G.L. Amidon Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach Mol. Pharm. 8 2011 2358 2367
25. F.G. Hayden, A.D. Osterhaus, J.J. Treanor, D.M. Fleming, F.Y. Aoki, K.G. Nicholson, A.M. Bohnen, H.M. Hirst, O. Keene, and K. Wightman Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 influenza study group N. Engl. J. Med. 337 1997 874 880
26. B. He, P. Lin, Z.R. Jia, W.W. Du, W. Qu, L. Yuan, W.B. Dai, H. Zhang, X.Q. Wang, J.C. Wang, X. Zhang, and Q. Zhang The transport mechanisms of polymer nanoparticles in Caco-2 epithelial cells Biomaterials 34 2013 6082 6098
27. C. He, Y. Hu, L. Yin, C. Tang, and C. Yin Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles Biomaterials 31 2010 3657 3666
28. W.M. Ibrahim, A.H. ALOmrani, and A.E. Yassin Novel sulpiride-loaded solid lipid nanoparticles with enhanced intestinal permeability Int. J. Nanopharm. 9 2014 129 144
29. M. Ismail The use of Caco-2 cells as an in vitro method to study bioavailability of iron Mal. J. Nutr. 5 1999 31 45
30. N. Kawai, H. Ikematsu, N. Iwaki, O. Tanaka, Y. Yamanishi, N. Hirotsu, and S. Kashiwagi Zanamivir treatment is equally effective for both influenza A and influenza B Clin. Infect. Dis. 44 2007 1666
31. P. Kish, J.S. Kim, B. Roessler, S. Campbell, and J. Hilfinger Bile acid conjugates improve the oral bioavailability of the neurominidase inhibitor zanamivir Antiviral Res. 74 2007 A45 A46
32. S.A. Kulkarni, and S.S. Feng Effects of particle size and surface modification on cellular uptake and biodistribution of polymeric nanoparticles for drug delivery Pharm. Res. 30 2013 2512 2522
33. A.K. Kushwaha, P.R. Vuddanda, P. Karunanidhi, S.K. Singh, and S. Singh Development and evaluation of solid lipid nanoparticles of raloxifene hydrochloride for enhanced bioavailability BioMed Res. Int. 2013 2013 1 9
34. H. Lennernäs, K. Palm, U. Fagerholm, and P. Artursson Comparison between active and passive drug transport in human intestinal epithelial (Caco-2) cells in vitro and human jejunum in vivo Int. J. Pharm. 127 1996 103 107
35. H.L. Li, X.B. Zhao, Y.K. Ma, G.X. Zhai, L.B. Li, and H.X. Lou Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles J. Control. Release 133 2009 238 244
36. W.J. Li, X.R. Li, Y.J. Gao, Y.X. Zhou, S.J. Ma, Y. Zhao, J.W. Li, Y. Liu, X.L. Wang, and D.D. Yin Inhibition mechanism of P-glycoprotein mediated efflux by mPEG-PLA and influence of PLA chain length on P-glycoprotein inhibition activity Mol. Pharm. 11 2014 71 80
37. J.W. Loh, M. Saunders, and L.Y. Lim Cytotoxicity of monodispersed chitosan nanoparticles against the Caco-2 cells Toxicol. Appl. Pharm. 262 2012 273 282
38. G.J. Mahler, M.B. Esch, E. Tako, T.L. Southard, S.D. Archer, R.P. Glahn, and M.L. Shuler Oral exposure to polystyrene nanoparticles affects iron absorption Nat. Nanotechnol. 7 2012 264 271
39. L. Priano, D. Esposti, R. Esposti, G. Castagna, C. De Medici, F. Fraschini, M.R. Gasco, and A. Mauro Solid lipid nanoparticles incorporating melatonin as new model for sustained oral and transdermal delivery systems J. Nanosci. Nanotechnol. 7 2007 3596 3601
40. C. Schimpel, B. Teubl, M. Absenger, C. Meindl, E. Fröhlich, G. Leitinger, A. Zimmer, and E. Roblegg Development of an advanced intestinal in vitro triple culture permeability model to study transport of nanoparticles Mol. Pharm. 11 2014 808 818
41. R. Shegokar, K.K. Singh, and R.H. Müller Production & stability of stavudine solid lipid nanoparticles-from lab to industrial scale Int. J. Pharm. 416 2011 461 470
42. Q.T. Shubhra, A.F. Kardos, T. Feczkó, H. Mackova, D. Horák, J. Tóth, G. Dósa, and J. Gyenis Co-encapsulation of human serum albumin and superparamagnetic iron oxide in PLGA nanoparticles: part I. Effect of process variables on the mean size J. Microencapsul. 31 2014 147 155
43. A.C. Silva, A. Kumar, W. Wild, D. Ferreira, D. Santos, and B. Forbes Long-term stability: biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles Int. J. Pharm. 436 2012 798 805
44. V. Uskokovic, P.P. Lee, L.A. Walsh, K.E. Fischer, and T.A. Desai PEGylated silicon nanowire coated silica microparticles for drug delivery intestinal epithelium Biomaterials 33 2012 1663 1672
45. J. Varshosaz, M. Tabbakhian, and M.Y. Mohammadi Formulation and optimization of solid lipid nanoparticles of buspirone HCl for enhancement of its oral bioavailability J. Liposome Res. 20 2010 286 296
46. M. von Itzstein, W.Y. Wu, G.B. Kok, M.S. Pegg, J.C. Dyason, B. Jin, T. Van Phan, M.L. Smythe, H.F. White, and S.W. Oliver Rational design of potent sialidase-based inhibitors of influenza virus replication Nature 363 1993 418 423
47. K. Westesen, and H. Bunjes Do nanoparticles prepared from lipids solid at room temperature always possess a solid lipid matrix? Int. J. Pharm. 115 1995 129 131
48. N.T. Wetherall, T. Trivedi, J. Zeller, C. Hodges-Savola, J.L. McKimm-Breschkin, M. Zambon, and F.G. Hayden Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network J. Clin. Microbiol. 41 2003 742 750
49. S.H. Yu, D.W. Tang, H.Y. Hsieh, W.S. Wu, B.X. Lin, E.Y. Chuang, H.W. Sung, and F.L. Mi Nanoparticle-induced tight-junction opening for the transport of an anti-angiogenic sulfated polysaccharide across Caco-2 cell monolayers Acta Biomater. 9 2013 7449 7459
50. Z.W. Zhang, F. Gao, H.H. Bu, J.S. Xiao, and Y.P. Li Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats Nanomedicine 8 2012 740 747